Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $12.0 million.

  • Indivior Pharmaceuticals' Interest Expenses rose 909.09% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 2500.0%. This contributed to the annual value of $41.0 million for FY2024, which is 1714.29% up from last year.
  • Indivior Pharmaceuticals' Interest Expenses amounted to $12.0 million in Q3 2025, which was up 909.09% from $15.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Interest Expenses high stood at $15.0 million for Q2 2025, and its period low was -$14.0 million during Q4 2024.
  • In the last 4 years, Indivior Pharmaceuticals' Interest Expenses had a median value of -$7.5 million in 2022 and averaged -$571428.6.
  • The largest annual percentage gain for Indivior Pharmaceuticals' Interest Expenses in the last 5 years was 21000.0% (2024), contrasted with its biggest fall of 5555.56% (2024).
  • Over the past 4 years, Indivior Pharmaceuticals' Interest Expenses (Quarter) stood at -$8.0 million in 2022, then dropped by 12.5% to -$9.0 million in 2023, then crashed by 55.56% to -$14.0 million in 2024, then surged by 185.71% to $12.0 million in 2025.
  • Its Interest Expenses was $12.0 million in Q3 2025, compared to $15.0 million in Q2 2025 and $12.0 million in Q1 2025.